www.thermoscientific.com/aboutsepsis Every year, severe sepsis affects more than three quarters of a million patients—and as many as 40 percent of these patients die. Early identification of septic patients is crucial for physicians explains Dr. Eric Gluck at Chicago's Swedish Covenant Hospital. Studies show that patient outcomes significantly improve the earlier treatment can begin. Sepsis presents few specific clinical symptoms or signs in its early phases; however, physicians can deploy Procalcitonin biomarker testing as one of several evaluation tools to improve risk assessment for sepsis. To learn more about this test, click here: www.thermoscientific.com/aboutsepsis
Thermo Fisher Scientific products are distributed worldwide. Not all intended uses and applications mentioned in this video are registered in every country.
![](https://s2.save4k.ru/pic/bWBf2tFZWQY/maxresdefault.jpg)